|Budget Amount *help
¥2,100,000 (Direct Cost : ¥2,100,000)
Fiscal Year 1990 : ¥600,000 (Direct Cost : ¥600,000)
Fiscal Year 1989 : ¥1,500,000 (Direct Cost : ¥1,500,000)
1. pol region of HTLV-I integrated in the host DNA in ATL patients and HILV-I carriers was amplified by PCR method. Using a image analyzing of the products with 32P-labeled oligomer after dot hybridization the dose of HTLV-I genome was determined.
2. When DNA from a cell line containing one copy of HTLV-I, the diluted DNA and the intensity of dot hybridization of PCR products corresponded very well.
3. Based on these results, PBLs fram 134 cases of HTLV-I healthy carriers were analyzed. In the results, the negative cases were 1 %, less than 0.1 % equivalent was 18 %, 0.1-1 % equivalent was 34 %, 1-10 % equivalent was 42 %, more than 10 % was 5 the cases with negative antibody titer against HTLV-I showed negative in PCR.
4. When these results were analyzed based on the age, cases with less than 1 % equivalent decreased and cases with more. than 10 % equivalent increased with aging.
5. Viral genome dose in individual carriers correlated with the titer of anti-tax antibody.
6. When 22 samples from HAM patients were analyzed, they showed characteristic features in which low-dose group is less, and high-dose group is more than those of healthy carriers, suggesting that they are high responders.
7. When lymphoma-type ATL were analyzed, the lymph node cells showed high genetic dose and showed clonal bands in conventional Southern blot analysis. On the other hand, the PBLs of them showed generally low dose, and showed few clonal bands in Southern blot analysis. Thus, the possibility that ATL may occur fram even the individuals with low genome dose in PBLs.
8. As the genome dose showed high, the frequency of abnormal lymphocytes in peripheral blood became higher.